640. Development of a Laboratory Verification Protocol for Concurrent Detection of Bacterial, Fungal, and Antimicrobial Resistance Genes in a Multiplex Syndromic Joint Infection Panel
Monica Cronin, MS1; Taylor K. Fadgen, Bachelor of Science2; Lisa Ogden, BS3; Jeremy P. Green, BS4; Stephanie A. Thatcher, MS5; Rebecca C. Young, MS1; Brandon Hoebel, BS1; BioFire Diagnostics, LLC, Salt Lake City, Utah; 2ZepetoMetrix, LLC, Buffalo, New York.

Session: P-29. Diagnostics: Bacteriology/mycobacteriology

Background. Verification is a critical component of implementing a diagnostic test in a clinical lab and can be time consuming and costly. A verification protocol and organism panel were developed in collaboration with ZepetoMetrix, LLC to verify all analytic detections for the BioFire Joint Infection (JI) Panel6. The BioFire JI Panel detects 31 pathogens and 8 antimicrobial resistance (AMR) genes associated with joint contaminants from synovial fluid specimens.

Methods. A protocol was developed using prototype NATCell controls from ZepetoMetrix, synovial fluid, and the BioFire FilmArray 2.0 and the BioFire FilmArray Torch Systems. Control materials were tested in the presence of synovial fluid from pooled human donors. The 32 targets required for all analytic detections were divided into 5 pools of 6-7 analytes and then tested over multiple days on several systems.

Results. Preliminary outcomes were good with a cumulative positive detection rate of 100% (310/310) and expected negative detections of 99.3% (1182/1190) from 50 prototype BioFire Joint Panel test runs. AMRs were correctly identified in 50/50 (100%) replicates when a correlated bacterium was present. Unexpected detections of Streptococcus spp. (7/50) and Staphylococcus lugdunensis (1/50) were likely due to contaminants in the synovial fluid. Streptococcus spp. was confirmed by testing the synovial fluid in isolation.

Conclusion. Efficient performance verification may be achieved by combining 32 organisms/8 AMR into 5 pools and can be completed with 20 test runs in 4 days. The protocol shown provides multiple positive/negative detections per analyte and accurately detects AMR. The protocol and controls serve as a useful tool for providing reliable detections of targets over multiple days, operators and systems and offers a flexible solution for supporting verification needs.

The BioFire Joint Infection Panel is currently pending US FDA De Novo review. This product has not been evaluated by other global regulatory agencies for in vitro diagnostic use.

Not available for sale. Panel menu subject to change.

Disclosures. Monica Cronin, MS, BioFire Diagnostics, LLC (Employee) Taylor K. Fadgen, Bachelor of Science, BioFire Diagnostics, LLC (Employee) Lisa Ogden, BS, BioFire Diagnostics, LLC (Employee) Jeremy P. Green, BS, BioFire Diagnostics, LLC (Employee, Shareholder) Stephanie A. Thatcher, MS, BioFire Diagnostics (Employee) Rebecca C. Young, MS, BioFire Diagnostics, LLC (Employee) Brandon Hoebel, BS, ZepetoMetrix, LLC (Employee).

641. Clinical Predictors of Hospital-Acquired Bloodstream Infections
Radhika Sethi, MD1; Mehmehat Bhatia, DO2; Vivek Kak, MD3; Henry Ford Allegiance Health, Jackson, Michigan

Session: P-29. Diagnostics: Bacteriology/mycobacteriology

Background. Hospital-acquired bloodstream infections (HABSI) are associated with increased mortality and decreased hospital quality metrics. This has led to an increased focus on blood culture stewardship. Little data exists regarding predictive factors of bacteremia in hospitalized patients. We aim to determine what clinical characteristics in patients were predictive of HABSI.

Methods. Factors of bacteremia in hospitalized patients. We looked at different clinical parameters and laboratory investigations within 24 hours of drawing blood cultures. Clinical variables were age ≥18 years, time of blood draw (≤6 vs. >6 hours), WBC count (≥15 vs. <15 cells/µL), and C-reactive protein (CRP) (≥10 vs. <10 mg/dL). Stepwise logistic regression analysis was used for predictive statistical models.

Results. In a cohort of 481 patients with hospital-acquired bacteremia, 350 cases had true bacteremia and 131 cases were contaminated blood cultures. Stepwise regression analysis showed that white blood cell (WBC) count ≥12,000 cells/µL, lymphocyte count ≤1000/mm3, creatinine ≥2.0 mg/dL, and oral temperature >38°C (100.4°F) were associated with HABSI (R-squared= 0.06, p value= 0.002).

Conclusion. Our findings suggest that WBC count, lymphocyte count, creatinine, and oral temperature together can be used to develop appropriate blood culture stewardship models in the inpatient setting. This may help minimize unnecessary blood culture collections.

Disclosures. All Authors: No reported disclosures.

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
Vikas Gupta, PharmD, BCPS5; Kalvin Yu, MD6; Jason M Pogue, PharmD, BCPS, BCIDP7; Janet Weeks, PhD8; Cornelius J. Clancy, MD9; Becton, Dickinson and Company, Franklin Lakes, NJ; College of Pharmacy, University of Michigan, Ann Arbor, MI; University of Pittsburgh, Pittsburgh, PA

Session: P-29. Diagnostics: Bacteriology/mycobacteriology

Background. Carbapenem (Carb) minimum inhibitory concentration (MIC) breakpoints were lowered by the Clinical and Laboratory Standards Institute (CLSI) in 2016. Adoption of revised breakpoints is often slow, which may lead to under-reporting of Carb non-susceptibility (NS) by facilities. We compare facility-reported rates of Carb-NS ENT to the CLSI MIC breakpoints for a large nationwide collection of isolates in the United States (US) from 2016-2019.

Table 1: Comparison of Carb-NS ENT Facility Reported vs. CLSI MIC Breakpoints

| METIC | Facility Reported | Revised per CLSI |
|-------|------------------|------------------|
| R (≥2) | 4,749 (0.51%) | 5,684 (0.61%) |
| S (<0.5) | 931,342 (99.30%) | 929,822 (99.13%) |

Overall, 3,017,036/3,043,593 (99.2%) were classified as Carb-NS ENT. The CLSI MIC breakpoint for Carb-NS ENT was ≥4 mg/L for Carbapenem. Facility reported rates of Carb-NS ENT were 4,749 (0.51%) vs. 5,684 (0.61%) for Carbapenem R (≥2) and 931,342 (99.30%) vs. 929,822 (99.13%) for S (<0.5). Facility reported rates were lower than CLSI MIC breakpoints, indicating under-reporting of Carb-NS ENT.

Methods. Adults with a positive non-contaminant ENT culture (first isolate of a species by >36-hour period from blood, respiratory, urine, skin/wound, intra-abdominal, or other) in ambulatory/inpatient settings from January 1, 2016 to December 31, 2019 were evaluated (BD Insights Research Database). Facility-reported Carb-NS was defined as: susceptible (S), intermediate (I) or R to etapenem (ETP), imipenem (IPM), meropenem (MEM) and/or doripenem (DOR) per commercial panels. Where available, MICs were interpreted using CLSI 2010 MIC breakpoints (µg/mL): ≤0.5 (S), 1 (I), ≥2 (R) ETP and ≤1 (S), 2 (I), and ≥4 (R) IPM/MEM/DOR. For evaluable ENT isolates we compared susceptibility results as reported by the facility to CLSI MIC breakpoints.

Results. Overall, 77.4% (937,926/1,211,845) and 90.6% (2,157,785/2,381,824) non-duplicate ENT isolates with facility-reported susceptibility results also had interpretable MIC results for ETP and IPM/MEM/DOR, respectively (Tables). ETP R rates were 99.3% and 99.1% as reported by facilities and using CLSI criteria, respectively. S rates of other Carbs were 99.8% and 99.4% by facility reporting and CLSI criteria, respectively. Systematic application of CLSI breakpoints under-reported ETP-I and –R isolates by 24.2% and 16.4%, respectively, and identification of IPM/MEM/DOR-I and –R isolates by 31.3% and 22.7%, respectively.

Conclusion. Systematic application of CLSI breakpoints in 2016-19 would have had minimal impact on ENT R rates in the US. However, facility reporting failed to identify 18.8% of ETP R or 26.5% of IPM/MEM/DOR-R isolates. The clinical implications of this observation are unknown. Facilities should know their local impact on their patients.

Disclosures. Vikas Gupta, PharmD, BCPS, Becton, Dickinson and Company (Employee, Shareholder) Kalvin Yu, MD (BD Employee) Janet Weeks, PhD (Employee) Cornelius J. Clancy, MD, Merck (Grant/Research Support)

643. Evaluation of Rapid Blood Pathogen Identification Along with Antimicrobial Stewardship at an Academic Teaching Institution
Sharon Blum, PharmD7; Terrence McSweeney, PharmD2; Samad Tirmi, PharmD, BCIDP1; Brian Auditoire, PharmD5; Diane Johnson, MD7; Brian Malone, RPPh6; NYU Langone - Long Island, Mineola, NY; Yale New Haven Hospital, New Haven, CT; Yale New Haven Hospital, South Salem, NY; NYU Langone Long Island, Mineola, New York

Session: P-29. Diagnostics: Bacteriology/mycobacteriology

Background. Bloodstream infections are a major cause of morbidity and mortality in hospitalized patients. Prompt initiation of effective antimicrobials are essential to optimize patient outcomes. New diagnostic technologies rapidly identifying bacteria, viruses, fungi, and parasites in infections of various body sites; the paucity of literature determining if stewardship programs run by one trained pharmacist with rapid diagnostics decreases time to optimal antimicrobial therapy.

Methods. This was a retrospective chart review of positive bloodstream infections identified via rapid diagnostic technologies. The EHR of admitted adult patients

Abstracts • OFID 2021:8 (Suppl 1) • 5423